Login to Your Account

GW Pharma sees Sativex as add-on to Epidiolex as it regains U.S. rights from Otsuka

By Cormac Sheridan
Staff Writer

Wednesday, December 13, 2017

DUBLIN – Two years after a failed effort to develop the cannabinoid product Sativex (nabiximols) as a therapy for cancer pain in the U.S., GW Pharmaceuticals plc and Otsuka Pharmaceutical Co. Ltd. are finally terminating an alliance that dates back more than a decade.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription